ArticleTherapeutic advances in neurological disorders2025

Sustained-release oral dalfampridine appears to have no impact on upper extremity function in people with multiple sclerosis: a randomized controlled trial.

Shay Menascu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.